Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Piperazines. Found 20 abstracts

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algul H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. The New England journal of medicine. 2019 Jul 25;381(4):317-27.   PMCID: PMC6810605
Hulse M, Caruso LB, Madzo J, Tan Y, Johnson S, Tempera I. Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1. PLoS Pathog. 2018 Nov;14(11):e1007394.   PMCID: PMC6237423
Liu B, Tang L, Zhang X, Ma J, Sehgal M, Cheng J, Zhang X, Zhou Y, Du Y, Kulp J, Guo JT, Chang J. A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists. Antiviral research. 2017 Nov;147:37-46.   PMCID: PMC5789800
Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017 Dec 28;130(26):2848-59.   PMCID: PMC5746670
Czyz M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. 2016 Nov 15;7(46):75551-60.   PMCID: PMC5342760
Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, Lu QS, Singh S, Yang DH, Talele TT, Ambudkar SV, Chen ZS. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One. 2011 Jan;6(4):e19329.   PMCID: PMC3084276
von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?. Cancer Treat Rev. 2011 Jun;37(4):291-9.   PMCID: not NIH funded
von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?. Oncology (Williston Park). 2009 Jan;23(1):65-6.   PMCID: PMC 2861343
Belinsky MG, Rink L, Cai KQ, Ochs MF, Eisenberg B, Huang M, von Mehren M, Godwin AK. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell cycle (Georgetown, Tex). 2008 Oct;7(19):2949-55.   PMCID: PMC2626174
Patel BB, He YA, Li XM, Frolov A, Vanderveer L, Slater C, Schilder RJ, von Mehren M, Godwin AK, Yeung AT. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics. 2008 May;5(3-4):137-49.
Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92.   PMCID: PMC2448846
Tarn C, Godwin AK. The molecular pathogenesis of gastrointestinal stromal tumors . Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S7-17.
von Mehren M. Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies. Current oncology reports. 2006 May;8(3):192-7.
Dushkin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Current treatment options in oncology. 2005 Mar;6(2):115-20.
Tarn C, Godwin AK. Molecular research directions in the management of gastrointestinal stromal tumors. Current treatment options in oncology. 2005 Nov;6(6):473-86.
Findlay VJ, Townsend DM, Saavedra JE, Buzard GS, Citro ML, Keefer LK, Ji X, Tew KD. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Molecular Pharmacology. 2004 May;65(5):1070-9.
Eisenberg BL. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. Oncology (Huntingt). 2003 Nov;17(11):1615-20; discussion 1620, 1623, 1626 passim.
Eisenberg BL, von Mehren M. Pharmacotherapy of gastrointestinal stromal tumours. Expert Opin Pharmacother. 2003 Jun;4(6):869-74.
von Mehren M. Recent advances in the management of gastrointestinal stromal tumors. Current oncology reports. 2003 Jul;5(4):288-94.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England journal of medicine. 2002 Aug 15;347(7):472-80.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Piperazines

Piperazines drug therapy Pyrimidines pharmacology Antineoplastic Agents genetics antagonists & inhibitors therapeutic use Gastrointestinal Stromal Tumors metabolism drug effects pathology Signal Transduction Female Mutation Human Neoplasm Drug Resistance Gastrointestinal Neoplasms Phthalazines Mice Tumor Cell Line Protein Kinase Inhibitors administration & dosage Proto-Oncogene Proteins c-kit Neoplastic Gene Expression Regulation Male Neoadjuvant Therapy 0 (Piperazines) Survival Analysis Treatment Outcome adverse effects Prognosis 152459-95-5 (imatinib) me [Metabolism] DNA Repair mortality Stromal Cells pharmacokinetics Ovarian Neoplasms Platelet-Derived Growth Factor Receptors 0 (Pyrimidines) Protein-Tyrosine Kinases Adult 80 and over Aged Protein-Tyrosine Kinase Drug Delivery Systems Aged tu [Therapeutic Use] Adjuvant Chemotherapy Pyrroles dt [Drug Therapy] surgery secondary Neoplasm Metastasis enzymology Proto-Oncogene Protein c-kit Proto-Oncogene Proteins c-akt chemistry Drug Synergism Poly(ADP-ribose) Polymerase Inhibitors methods Risk Assessment Cultured Tumor Cells Platelet-Derived Growth Factor alpha Receptor 72025-60-6 (Leukotriene C4) Enzyme Activation Melanoma Type 5 Cyclic Nucleotide Phosphodiesterases Maximum Tolerated Dose Hypoxia-Inducible Factor 1 4-Aminobenzoic Acid Species Specificity mo [Mortality] Thrombopoietin Receptors Gene Amplification 3T3 Cells 10102-43-9 (Nitric Oxide) Prodrugs Middle Age 4-dinitro-5-(N-methyl-N-4-carboxyphenylamino)phenyl 0 (O(2)-(2 Gene Expression Profiling Middle Aged Interferon Inducers blood p38 Mitogen-Activated Protein Kinases Maintenance Chemotherapy Small Interfering RNA Remission Induction aa [Analogs & Derivatives] Molecular Models 2-diolate) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1 Transcriptional Activation JNK Mitogen-Activated Protein Kinases Nitric Oxide 4-dinitrophenyl) 0 (O(2)-(2 IGF Type 1 Receptor Local Neoplasm Recurrence Clinical Trials Cell Line 150-13-0 (4-Aminobenzoic Acid) Host-Pathogen Interactions P-Glycoprotein Clinical Trials as Topic Dacarbazine Pancreatic Neoplasms ai [Antagonists & Inhibitors] Animal Disease Models deficiency US Gov't Research Support-PHS Human Herpesvirus 4 Histones Multidrug Resistance-Associated Proteins Imidazoles Gene Silencing synthetic lethality Mitogen-Activated Protein Kinases PARP1 inhibitor Cultured Cells Biological Availability Isoenzymes N-dimethylamino)diazen-1-ium-1 1-N-2-diolate) physiopathology Randomized Controlled Trials Viral Matrix Proteins Adenocarcinoma Double-Blind Method 0 (Isoenzymes) Cell Division ge [Genetics] 0 (Multidrug Resistance-Associated Proteins) Cell Survival Myeloproliferative Disorders Double-Stranded DNA Breaks Platelet-Derived Growth Factor) EC 2-7-1-112 (Receptors Heterografts Sulfones Adolescent US Gov't Support-Non-PHS Mass Spectrometry DNA Mutational Analysis EC 2-7-1-37 (Mitogen-Activated Protein Kinases) EC 2-7-1-37 (JNK Mitogen-Activated Protein Kinases) KB Cells de [Drug Effects] BRCA2 Genes pc [Prevention & Control] Antiviral Drug Discovery Sting EC 2-7-1-37 (p38 Mitogen-Activated Protein Kinases)
Last updated on Friday, January 03, 2020